Delving into the Latest Updates on Ipilimumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)

+ [17]

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [12]

Active Indication

Microsatellite instability-high Rectal CancerPD-L1 positive Non-Small Cell Lung CancerMetastatic hepatocellular carcinoma+ [292]

Inactive Indication

Acute bilineal leukemiaAcute Biphenotypic LeukemiaAcute lymphoblastic leukemia recurrent+ [131]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

The University of Texas MD Anderson Cancer Center

National Cancer Institute

+ [16]

Inactive Organization

Checkmate Pharmaceuticals, Inc.

University of Southern CaliforniaJonsson Comprehensive Cancer Center

+ [11]

License Organization

Nektar Therapeutics

Inspirna, Inc.

Gritstone bio, Inc.

+ [8]

Drug Highest PhaseApproved

First Approval Date

United States (25 Mar 2011),

Melanoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Priority Review (United States), Conditional marketing approval (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 143797L

Source: *****

Sequence Code 9060585H

Source: *****

The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.

Start Date31 Dec 2025

Sponsor / Collaborator

Washington University School of Medicine

[+1]

NCT07128680

/ Not yet recruitingPhase 1IIT

A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)

This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. EXL01 is a live biotherapeutic product containing a strain of bacteria called Faecalibacterium prausnitzii. It may enhance a patient's response to treatment with immune checkpoint inhibitors like nivolumab and ipilimumab by altering the composition of the bacteria in the gut. Adding EXL01 to treatment with nivolumab and ipilimumab may be safe and more effective than giving nivolumab and ipilimumab alone.

Start Date05 Dec 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Ipilimumab

Login to view more data

100 Translational Medicine associated with Ipilimumab

Login to view more data

100 Patents (Medical) associated with Ipilimumab

Login to view more data

5,565

Literatures (Medical) associated with Ipilimumab

31 Dec 2025·OncoImmunology

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab

Article

Author: Bjursten, Sara ; Ny, Lars ; Lindén, Maria ; Levin, Max ; Zhao, Zhiyuan ; Pandita, Ankur ; Al Remawi, Hifaa ; Rudin, Anna

Combination CTLA-4 (ipilimumab) and PD-1 (nivolumab) checkpoint inhibition (dual-ICI) improves survival in patients with advanced melanoma. However, many patients also experience immune-related adverse events (irAE) that require systemic treatment with corticosteroids. Corticosteroids dampen the anti-tumoral response and may impair survival. Here, we investigated the association between irAE and overall survival as well as exposure to corticosteroids and second line immunosuppressants in dual ICI-treated patients with advanced melanoma (n = 205). Patients with irAE (n = 113) had superior OS compared to patients with no irAE (n = 92). The survival benefit persisted after adjusting for immortal time bias. Regarding specific irAE, patients with colitis, hepatitis, rheumatic irAE, hypophysitis, and skin-related irAE had improved OS after adjusting for negative baseline factors. A survival benefit persisted for hypophysitis (p = 0.03) and hepatitis (p = 0.04) after adjusting for immortal time bias, whereas rheumatic (p = 0.05) and skin-related irAE (p = 0.06) where borderline significant. Hepatitis and colitis required higher doses of corticosteroids for longer times and more often second-line immunosuppression compared to other irAE. In conclusion, irAE are associated with superior OS in patients with advanced melanoma treated with dual ICI. Hepatitis and hypophysitis were most strongly associated with better survival outcomes. Studies investigating the mechanisms underlying hepatitis and hypophysitis may identify important response mechanisms.

31 Dec 2025·OncoImmunology

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab

Article

Author: Baginska, Joanna ; Rodig, Scott J. ; Severgnini, Mariano ; Hodi, F. Stephen ; Chen, Jiajia ; Manuszak, Claire ; Brennick, Ryan ; Weirather, Jason L. ; Manos, Michael ; Ranasinghe, Srinika ; Liu, David ; Huang, Amy Y. ; Holovatska, Marta ; Hathaway, Emma ; Nazzaro, Matthew ; Giobbie-Hurder, Anita ; Tarantino, Giuseppe ; Pfaff, Kathleen L. ; Russell, Janice D.

Nivolumab plus ipilimumab (aCTLA-4/aPD-1) combination therapy has significantly improved clinical outcomes in patients with metastatic melanoma, with 50%-60% of patients responding to treatment, but predictors of response are poorly characterized. We hypothesized that circulating cytokines and peripheral white blood cells may predict response to therapy and evaluated 15 cytokines and complete blood counts (CBC with differentials) from 89 patients with advanced melanoma treated with combination therapy from three points in time: pre-treatment, one month and approximately three months after starting therapy. Clinical endpoints evaluated included durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS). A parsimonious predictive model was developed to identify cytokines predictors of response to combination therapy. In this study, we found that pre-treatment, patients with DCB had higher IL-23, lower CXCL6, and lower IL-10 levels. Lower NLR one month after starting therapy predicted better PFS and OS, primarily driven by an increase in absolute lymphocytes. A multivariate model demonstrated that baseline CXCL6, IL-10, IL-23 were independent predictors of therapy response, and the combined model has reached an area under the curve (AUC) of 0.79 in prediction of response to combination therapy. Our study identified baseline CXCL6, IL-23, and IL-10 as predictors of response to aCTLA4/aPD1 combination therapy among patients with metastatic melanoma. This study also provides a framework for identifying patients who are likely to respond to combination ICB, as well as a subset of patients with high risk of developing resistance and are thus in need of alternative therapeutic options, such as clinical trials.

31 Dec 2025·mAbs

Engineered ipilimumab variants that bind human and mouse CTLA-4

Article

Author: Barman, Ishita ; Diong, SJ ; Lee, Peter S. ; Bee, Christine ; Rajpal, Arvind ; Kumar, Anusha ; West, Sean M. ; Strop, Pavel ; Chau, Bryant ; Robison, Brett ; Chang, Olin ; Korman, Alan J. ; Moon, Thomas M.

Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9, which binds mouse CTLA-4, is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. In this work, we reveal that 9D9 has significant biophysical dissimilarities to therapeutic CTLA-4 antibodies. The 9D9-mCTLA4 complex crystal structure was determined and shows that the surrogate antibody binds an epitope distinct from ipilimumab and tremelimumab. In addition, while ipilimumab has pH-independent binding to hCTLA-4, 9D9 loses binding to mCTLA-4 at physiologically relevant acidic pH ranges. We used phage and yeast display to engineer ipilimumab to bind mouse CTLA-4 with single-digit nM affinity from an initial state with no apparent binding. The engineered variants showed pH-independent and cross-reactive binding to both mouse and human CTLA-4. Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models.

913

News (Medical) associated with Ipilimumab

11 Dec 2025

·www.prnewswire.com

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free survival (PFS) data from this trial in the first quarter 2026 to support a potential accelerated approval filing in the United States. Median overall survival (mOS) data from OptimUM-02, once available, will be used to support a potential full approval filing. Metastatic uveal melanoma is a rare, aggressive form of ocular cancer with limited treatment options and historically poor survival outcomes. "We are very pleased to announce that we have achieved the target enrollment to enable potential full approval filing in our Phase 2/3 registration-enabling trial of darovasertib in combination with crizotinib in first-line HLA*A2-negative metastatic uveal melanoma. This milestone reflects both the clear unmet need in metastatic uveal melanoma, as well as the strong clinical interest in our darovasertib program. Moreover, the promising overall survival data and broader clinical efficacy demonstrated in the recently reported median overall survival results from the Phase 1/2 clinical trial (OptimUM-01) of this combination in metastatic uveal melanoma are indicative of the clinical potential of darovasertib to meaningfully impact patients with this devastating disease. With target full enrollment now complete, we look forward to the availability of median PFS data we project from OptimUM-02 in the first quarter of next year, and, if approved, making darovasertib in combination with crizotinib available to patients with HLA*A2-negative metastatic uveal melanoma as a first-line treatment as expeditiously as possible," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. OptimUM-02 is a multi-arm, multi-stage, open-label Phase 2/3 trial with patients randomized to receive either the darovasertib and crizotinib combination or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine). The primary endpoints are median PFS and median OS, which will be used to support a potential accelerated approval and full approval in the United States, respectively. In October 2025, IDEAYA presented data from its single-arm, Phase 2 trial (OptimUM-01) of the darovasertib and crizotinib combination at the Society for Melanoma Research (SMR) Congress that demonstrated a 21.1 month median OS and 7.0 months median PFS in 1L mUM, including both HLA*A2-negative and HLA*A2-positive patients. Darovasertib has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation as neoadjuvant therapy in enucleation recommended primary uveal melanoma (UM) and Fast Track designation for darovasertib in combination with crizotinib in adult patients with metastatic UM. Darovasertib has also been designated as an Orphan Drug by the U.S. FDA in UM, including in metastatic UM. IDEAYA is currently enrolling patients in a pivotal Phase 3 trial of single-agent darovasertib in the neoadjuvant setting of primary UM (OptimUM-10). About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of clinical trial programs and updates, including enrollment achievements, regulatory updates, clinical trial data readouts; (ii) the potential for an accelerated and full approval for darovasertib; (iii) the potential therapeutic benefit of darovasertib, including in combination with crizotinib; and (iv) the timing of development and regulatory milestones. Clinical trial results, preliminary or otherwise, are not necessarily predictive of future clinical trial results and/or approval. Neither Breakthrough Therapy nor Orphan Drug Designation necessarily translates into approval of the drug. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing and commercializing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission. Investor and Media Contact IDEAYA Biosciences Joshua Bleharski, Ph.D. Chief Financial Officer [email protected] SOURCE IDEAYA Biosciences, Inc. 21% more press release views with Request a Demo

Clinical ResultOrphan DrugPhase 3Fast TrackBreakthrough Therapy

09 Dec 2025

·endpoints.news

Stealthy biotech Sidera Bio raises $109M; Assembly's data for oral herpes drugs

Plus, news about Scancell Holdings, Immutep, Dr. Reddy’s, Sensorion and Convergen: 💵 Sidera Bio reportedly gets $109M: Investors including Novo Holdings, Forbion, RA Capital Healthcare Fund and Gilde Healthcare participated in the Series A round, according to a report in MarketWatch and a LinkedIn post from CVX Ventures. Forbion holds up to a third of Sidera, and Novo had already provided seed funding to the stealthy Danish biotech. There may be further funding to come, though neither Sidera nor Forbion would comment on the deal. Sidera was reportedly founded under the name GhostBio in 2023. The startup is believed to have licensed a GLP-1/GIP and FGF21 agonist from the Chinese company Lepu Medical Technology in October. The drug is intended for obesity and other metabolic disorders. Sidera obtained ex-China rights to the Phase 2-stage drug, codenamed MWN105, via Lepu’s subsidiary Minwei Biotech, in exchange for an upfront payment of $35 million plus near-term milestone payments, the news website Synopulse reported . Minwei also took a 9.9% equity stake in Sidera, and could get up to $1.01 billion in biobucks. Another Chinese company has a drug with the same mechanism, and is also seeking a Western partner. Zhejiang Doer Biologic told Endpoints News that it intends to start Phase 3 trials of its triple agonist candidate for high triglyceride levels next year. — Elizabeth Cairns 💊 Assembly Biosciences’ oral herpes drugs post encouraging early data : One of the pills, ABI-1179, cut the HSV-2 shedding rate by 98% and high viral load shedding rate by more than 99% over placebo, according to interim data from two Phase 1b trials. Subjects given a 50 mg weekly dose had a 91% reduction in virologically confirmed genital lesions, which Assembly said exceeded its expectations. In another Phase 1 trial, a monthly dose of a different antiviral, called ABI-5366, decreased the HSV-2 shedding rate and high viral load shedding rate by 76% and 81%, respectively. It yielded an 88% cut in virologically confirmed genital lesion rate. Assembly is working to move ABI-1179 into Phase 2. It is also planning longer Phase 2 trials of a once-weekly version of ABI-5366 to start mid-2026. Both drugs are herpes simplex virus helicase-primase inhibitors; under a 2023 agreement Gilead has an option to license Assembly’s helicase-primase inhibitor program following the completion of the Phase 1b trials. — Elizabeth Cairns 🧬 Scancell Holdings’ DNA-based skin cancer vaccine beats standard care: A new data cut from the third cohort in the Phase 2 SCOPE trial showed that the iSCIB1+ therapy significantly improved progression-free survival in patients with advanced melanoma. The drug was given on top of checkpoint inhibitors as first-line therapy, and yielded a 74% PFS rate at 16 months. The UK biotech said this beats the PFS of 50% at 11.5 months seen with the standard care regimen of Opdivo and Yervoy. Overall response rate for the target population in the third cohort was 56%, with a disease control rate of 79%. Early overall survival data showed a 14% improvement over standard care at 26 months. The data will be presented at the ESMO IO conference on Thursday, and Scancell is aiming to start Phase 3 trials in late 2026. It is seeking a partner, and looking at financing options for the drug. — Elizabeth Cairns 🤝 Immutep makes a deal with Dr. Reddy’s: The companies inked a licensing agreement in which Dr. Reddy’s gets development and commercialization rights to the investigational cancer drug eftilagimod alpha except for North America, Europe, Japan and Greater China. Dr. Reddy’s will pay $20 million upfront, with $349.5 million in milestone payments on the table. There’s also double-digit royalties on commercial sales in markets covered by the deal. — Reynald Castaneda 👂 Sensorion’s deafness gene therapy trial to continue : The data monitoring committee overseeing the Phase 1/2 Audiogene trial of SENS-501 has raised no safety concerns, the French company said Monday. The study, testing intra-cochlear administration of the gene therapy in infants and toddlers with a form of congenital deafness caused by mutations in the gene for otoferlin, can therefore continue. Sensorion said that so far, two of the three patients in the trial’s second cohort had shown early improvements within three months of receiving the therapy. Further data are due in the first quarter of next year. — Elizabeth Cairns 🇨🇳 Chinese biotech raises $10M: Convergen will use its seed funding to work on its bifunctional degrader platform called TrimTAC and its R&D pipeline in neurodegenerative disorders. Qiming Venture Partners supported the raise. — Reynald Castaneda

Clinical ResultPhase 1Phase 2VaccineLicense out/in

08 Dec 2025

·www.fiercepharma.com

Meds from Pfizer, Lilly, J&J and more secure spots in China's 1st private insurance formulary

The 19 meds selected for China's Commercial Health Insurance Innovative Drug Catalogue include drugs from Pfizer, Eli Lilly, BeiGene and more. Nineteen novel drugs have been selected for inclusion in the first iteration of China's Commercial Health Insurance Innovative Drug Catalogue, portending potential access benefits as the program gains momentum.The list, which was unveiled by China's National Healthcare Security Administration (NHSA) at a Dec. 7 press conference in Guangzhou, was whittled down from 24 drugs that entered final pricing negotiations and 121 that initially passed a formal review, according to local reports. The catalog is set to take effect from Jan. 1, 2026, and prioritizes innovative drugs with “high levels of innovation, significant clinical value, substantial patient benefits, and coverage exceeding the scope of basic medical insurance,” the NHSA explained in a disclosure.Among the drugs that made the list (PDF, Chinese) are several CAR-T therapies, plus targeted cancer treatments including BeiGene’s HER2 bispecific Ziihera, Pfizer’s multiple myeloma med Empliciti, Bristol Myers Squibb’s Yervoy and Johnson & Johnson’s Darzalex. Alzheimer’s disease treatments from Eli Lilly and partners Eisai and Biogen made the grade, as well.Unlike the well-established National Reimbursement Drug List, which ensures coverage under the state-run national medical insurance scheme, drugs that made the inaugural commercial insurance roster won’t enjoy any guaranteed coverage. Instead, drugs on the new formulary are recommended for commercial health coverage. The formulary is expected to be gradually incorporated into commercial insurance programs backed by local governments. These programs, already available to residents at a relatively low out-of-pocket premium in some large Chinese cities, are considered supplemental to the national insurance scheme, with some already offering different levels of coverage for some pricey medicines, such as CAR-Ts. However, this pathway is not considered an enforceable policy but rather a recommendation. Each commercial insurance company is still free to decide which drugs to include.“With more new drugs added to the catalog, the level of clinical drug use will steadily improve, effectively boosting the pharmaceutical industry's confidence in increasing research and innovation, and providing greater protection for the health of the people,” the NHSA said in its release.Shanghai-based CAR-T maker CARsgen Therapeutics, which earned a place on the list with its multiple myeloma cell therapy zevor-cel, says its inclusion can “help further alleviate the financial burden on patients and enhance the accessibility of advanced cell therapies,” co-founder Huamao Wang, Ph.D., said in a release, adding that the company is committed to “contributing to the 'Healthy China' initiative.” The Healthy China initiative is a key national priority for the Chinese government amid rising rates of cancer and cardiovascular disease, prompting a focus on policy pushes in the health vein.

Cell TherapyImmunotherapy

100 Deals associated with Ipilimumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04603	Ipilimumab	L01XC11	DB06186

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Microsatellite instability-high Rectal Cancer	Japan	Bristol-Myers Squibb KK	25 Aug 2025
PD-L1 positive Non-Small Cell Lung Cancer	China	Bristol-Myers Squibb Pharma EEIG	22 Jul 2025
Metastatic hepatocellular carcinoma	Australia	Bristol-Myers Squibb Australia Pty Ltd.	27 Jun 2025
Advanced Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Mismatch repair-deficient Colonic Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma	United States	Bristol Myers Squibb Co.	27 May 2022
Esophageal Carcinoma	Japan	Bristol-Myers Squibb KK	26 May 2022
Hepatocellular Carcinoma	United States	Bristol Myers Squibb Co.	10 Mar 2020
Melanoma, Cutaneous Malignant	United States	Bristol Myers Squibb Co.	10 Jul 2018
Colorectal Cancer	United States	Bristol Myers Squibb Co.	16 Apr 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	30 Jan 2022
Bladder Cancer	Phase 3	United States	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	30 Jan 2022
HER2 negative Gastric Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Japan	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Taiwan Province	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
Glioblastoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Gliosarcoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Bristol Myers Squibb Co.	08 Oct 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04079712 (CTgov)	Phase 2	Large cell neuroendocrine carcinoma \| Small Cell Carcinoma \| Islet Cell Carcinoma ... View more	17	Ipilimumab+Nivolumab+Cabozantinib S-malate	qnozvmqgmy(yslkdkthck) = gdwbygxntg sdivcllnsb (lkyvqscnlm, rnfzybmbmu - qoicqdwvjv) View more	-	12 Dec 2025
NCT03305445 (ASH2025)	Phase 1/2	Diffuse Large B-Cell Lymphoma	6	Nivolumab/ipilimumab-primed “immunotransplant” (IT)	citnidfots(yvihrhqftg) = auonnfuhay odibspdfpv (locoanezvn ) View more	Positive	06 Dec 2025
NCT03388632 (Phase 1 study, CTgov)	Phase 1	Metastatic Solid Tumor \| Refractory Cancer \| Recurrent Carcinoma	31	ipilimumab+nivolumab+rh IL-15 (All Participants in Escalation Phase of Arm C)	nmwiyibdln = cbmzojrmsj etlpicnryr (emcmclwuhh, qviapavvpv - asirabhvjf)	-	03 Dec 2025
NCT03388632 (Phase 1 study, CTgov)	Phase 1		31	Recombinant Human Interleukin (rH IL-15)+Nivolumab (Arm A Doublet A - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Nivolumab 240mg)	hwaapqvmsm = bwliirnsaj kqnmhlhgng (rewvgfimny, uijwxdiavy - szxltvaods) View more	-	03 Dec 2025
NCT04021043 (Phase I/II study of BMS-986156, CTgov)	Phase 1/2	Metastatic Lung Cancer \| Liver metastases \| Metastatic Solid Tumor ... View more	51	BMS-986156+Ipilimumab (Ipilimumab + BMS-986156 Arm (30 mg/kg))	owkxdxrhgq = wzddzgdxrz xgkdmcorba (fvxtsrbmgg, veosmcmavl - secqlrrxyz) View more	-	03 Dec 2025
NCT04021043 (Phase I/II study of BMS-986156, CTgov)	Phase 1/2		51	BMS-986156+Ipilimumab (Ipilimumab + BMS-986156 Arm (100 mg/kg))	owkxdxrhgq = qwuteylivr xgkdmcorba (fvxtsrbmgg, qvzpelgqhs - uvdbpkplaa) View more	-	03 Dec 2025
NCT04969887 (MOST-CIRCUIT, Pubmed \| JAMA Oncol)	Phase 2	Microsatellite instability-high cancer dMMR \| MSI-H	52	IpilimumabNivolumab + IpilimumabNivolumabb	maxdybplru(ebjicolnfn) = gavuuugaoo cnwezkkbam (ucdubiakvs, 50 - 75) View more	Positive	13 Nov 2025
ASN2025	Not Applicable	Renal Cell Carcinoma	488	immune checkpoint inhibitors (Patients with systemic AID)	vovlbagsdw(ojyqpxfljo) = The rates of immune-related adverse outcomes were similar between cohorts, including steroid initiation (54% in AID vs 62% in controls), colitis (17.1% vs 17.6%), immune hepatitis (7.1% vs 9.5%), adrenalitis (4.2% vs 4.2%), hypothyroidism (10.4% vs 10.9%), hyperthyroidism (2.2% vs 2.7%), and peripheral neuropathy (1.2% vs 1.5%). Hypophysitis occurred more frequently in the autoimmune cohort (4.1% vs 0%), though absolute event rates were low. dabmqmkbhr (lbcvmcjfrp )	Positive	06 Nov 2025
ASN2025	Not Applicable	Renal Cell Carcinoma	488	immune checkpoint inhibitors (matched controls without AID)		Positive	06 Nov 2025
NCT02113657 (SITC2025)	Phase 3	Metastatic castration-resistant prostate cancer	27	Ipilimumab	mdgzebzwfd(cslontochv) = oadewtpgxe fmhyrbapok (twrctxewsn ) View more	Positive	05 Nov 2025
NCT04117087 (SITC2025)	Phase 1	Metastatic Microsatellite Stable Colorectal Carcinoma MMRp/MSS	13	mKRAS-VAX + nivolumab + ipilimumab	ckluigngox(wddwxefces) = svneiqwzzz heqrwuvtfb (akzmwyaxto ) View more	Positive	05 Nov 2025
NCT03391869 (LONESTAR, SITC2025)	Phase 3	metastatic non-small cell lung cancer	10	Ipilimumab and Nivolumab + platinum doublet chemotherapy	rhtlwevkbs(qsgdcgkepi) = kdlkomtevp ebmlnfifaz (cokjgusckp ) View more	Positive	05 Nov 2025
SITC2025	Not Applicable	Locally Advanced Melanoma	11	Ipilimumab and nivolumab	kjiogyfymc(afhplqewqm) = whxmkgxlpi bzhrpwufig (pifkimcwem ) View more	Positive	05 Nov 2025
SITC2025	Not Applicable	Locally Advanced Melanoma	11	Relatlimab and nivolumab	czuuqqrnqt(qxhvnserua) = hbzmsvtxbp ljxoktotrz (aaeivxktdf )	Positive	05 Nov 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data